Commercial Readiness:
In today’s tighter funding environment, a high valuation is no longer guaranteed by historical revenue alone. Investors are looking deeper into the quality, predictability, and scalability of your commercial engine. To bridge the gap between internal operations and external investment standards, Zymewire is joined by the specialized expertise of Bourne Partners and Ilikos Consulting Group.
Join us for a conversation that explores the intersection of mid-market investment banking and frontline commercial strategy. We will unpack the specific financial benchmarks and operational frameworks that transform a Life Sciences service provider from a functional business into a premium, de-risked acquisition target.
Save your Spot
Can’t join us live on February 11th? Register anyway and we’ll send the full session recording along with a summary of the key strategic takeaways.
Ryan Silvester
Vice President
Bourne Partners
Ryan is a specialist in global M&A and financing advisory with a dedicated focus on Pharma Services and Healthcare Technology. Representing Bourne Partners, a firm with a 25-year legacy at the forefront of healthcare finance, Ryan helps Life Sciences businesses navigate complex sell-side and buy-side transactions. His expertise lies in identifying the specific value drivers that bridge the gap between a company's current operations and its ultimate investment potential within the global healthcare ecosystem.
Elias Sayias
Founder
Ilikos Consulting Group
Elias is a clinical research veteran with over 15 years of experience bridging the gap between clinical operations and global commercial strategy. As the founder of ILIKOS Consulting Group, he has secured over $250M in new revenue for CROs and MedTech organizations by implementing tactical, market-driven go-to-market solutions. He is dedicated to helping service providers move beyond traditional sales to build sophisticated, high-growth commercial engines.
Ali Babar
Sr. Business Development Manager
Zymewire
With a foundation in multidisciplinary scientific research spanning psychiatry and chemical engineering, Ali brings a data-driven, analytical lens to the commercial landscape. He has spent years advising commercial teams within the biotech and pharma services sectors, helping them move beyond traditional prospecting to build sophisticated, high-performance sales engines. At Zymewire, he focuses on equipping organizations with the intelligence and frameworks necessary to identify market signals and drive sustainable, scalable growth.